摘要
目的探讨沙利度胺联合马法兰+泼尼松化疗方案治疗多发性骨髓瘤(MM)的临床疗效及不良反应。方法选取2008年10月至2013年1月在鄂州市中心医院血液科住院治疗的MM患者55例,按随机数字表法分为对照组27例,采用马法兰+泼尼松化疗方案予以治疗;观察组28例,在对照组治疗基础上加用沙利度胺治疗。观察两组临床疗效、M蛋白、骨髓瘤细胞、β2微球蛋白(β2-GM)和血红蛋白等指标变化。结果观察组治疗总有效率地显著高于对照组(78.6%vs 59.3%)(P<0.05);两组治疗后M蛋白、MM细胞和β2-GM等指标显著地下降,而血红蛋白明显上升,观察组改善更为明显(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论沙利度胺联合马法兰+泼尼松化疗方案治疗MM疗效显著,未出现严重不良反应,值得临床推广应用。
Objective To investigate the clinical curative effect and adverse reactions of thalidomide combined with melphalan and prednisene （ MP ） chemotherapy in the treatment of multiple myeloma（MM）. Methods According to the digital random method,55 patients with MMfrom Hematology Department of Ezhou Central Hospital were divided into the control group（ n = 27 ） treated with MP chemotherapy regimens,and observation group （ n = 28 ） treated with thalidomide on the base of control group. The clinical curative effect mad the changes of M protein,myeloma eens,[β2-microglobulin （β2-GM）, hemoglobin of the two groups were observed. Results The total effective of treatment group was significantly higher than that of control group （78.6% vs 59.3 % ） （ P 〈 0.05 ）. The M protein, MM cells and beta 2-GM of the two groups after treatment declined obviously,bnt hemoglobin increased,and the observation group improved more significantly （ P 〈 0.05 ）. There was no significant difference between the two groups about incidence of adverse reactions （ P 〉 0.05 ）. Conclusion The treatment of thalidomide combined with MP chemotherapy for multiple myeloma has a distinct curative effect, without serious adverse reaction,thus is worthy of clinical popularization and application.
出处
《医学综述》
2014年第17期3226-3227,共2页
Medical Recapitulate
关键词
沙利度胺
化疗
多发性骨髓瘤
Thalidomide
Chemotherapy
Multiple myeloma
